Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label randomized study of olanzapine pamoate depot versus oral olanzapine in outpatients with schizophrenia
2005-004157-99Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of olanzapine in schizophrenia (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Time to treatment discontinuation for any cause. Started Jan 2006; status: completed.
02
Drugs
olanzapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2005-004157-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004157-99.